Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$172.25M$138.35M$94.44M$84.16M
$37.8M$30.73M$14.04M$13.72M
$210.04M$169.08M$108.48M$97.88M
$210.04M$169.08M$108.48M$97.88M
-$210.04M-$169.08M-$108.48M-$97.88M
$7.18M$5.52M$3.95M$3.48M
$8.9M$7.93M$5.65M$5.45M
-$199.48M-146%-$161.15M-108%-$102.83M-$92.43M-$80.99M
-$200.45M-$161.54M-$103.21M-$92.2M
-$969K-$392K
$3.38M$2.41M$1.7M$1.97M
-$210.04M-$169.08M-$108.48M-$97.88M
-$209.47M-$168.51M-$107.85M-$97.15M
-$209.47M-$168.51M-$107.85M-$97.15M
-$210.04M-$169.08M-$108.48M-$97.88M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is MapLight Therapeutics, Inc. profitable?
MapLight Therapeutics, Inc. is not currently profitable: it reported a net loss of $199.5M over the trailing twelve months.
What is MapLight Therapeutics, Inc. 's earnings per share?
MapLight Therapeutics, Inc. 's diluted EPS over the trailing twelve months is $-95.86.
Where does MapLight Therapeutics, Inc. 's income statement data come from?
Every line is extracted from MapLight Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.